Codex DNA to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
Codex DNA, Inc. (Nasdaq: DNAY) announced it will release its third-quarter 2021 financial results on November 9, 2021, after market close. A conference call will follow at 2:00 p.m. PT to discuss the results and corporate highlights. The call can be accessed via phone or through the company's website. Codex DNA specializes in automated synthetic biology systems, including the BioXp™ platform, enhancing the speed and accuracy of DNA and RNA synthesis for various scientific applications.
- Codex DNA's BioXp™ system enables rapid, accurate DNA/RNA synthesis, enhancing productivity for laboratories.
- The company is a pioneer in automated synthetic biology, potentially leading to significant market opportunities.
- None.
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its third quarter 2021 financial results on Tuesday, November 9, 2021, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, November 9, 2021, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and recent corporate highlights.
The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.codexdna.com. The conference call can be accessed by dialing (888) 705-0127 (domestic) or (409) 937-8880 (international) and referring to conference ID 3669005. Please log in approximately 5 to 10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on Codex DNA’s website for 30 days.
About Codex DNA
Codex DNA is empowering scientists with the ability to create novel, synthetic biology solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate, and reproducible writing of DNA and mRNA for numerous downstream markets. The company’s award-winning BioXp™ system consolidates, automates, and optimizes the entire synthesis, cloning, and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA/RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com.
Contact:
Richard Lepke
Director of Investor Relations
(619) 840-5392
RichardL@codexdna.com
FAQ
What date will Codex DNA release its Q3 2021 financial results?
What time is the conference call for Codex DNA's Q3 2021 financial results?
How can I access Codex DNA's conference call?
What is Codex DNA's primary product?
